Comparative Pharmacology
Head-to-head clinical analysis: ATRIDOX versus DORYX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRIDOX versus DORYX.
ATRIDOX vs DORYX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATRIDOX (doxycycline hyclate) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases (MMPs) and reducing cytokine production.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain.
50 mg subgingival controlled-release insert applied by dental professional into periodontal pockets once every 3 months.
100 mg orally every 12 hours on day 1, then 100 mg orally every 24 hours. For severe infections: 100 mg orally every 12 hours.
None Documented
None Documented
Terminal half-life 16-18 hours; prolonged to 24-48 hours in renal impairment, requiring dose adjustment.
Terminal elimination half-life is 18-22 hours in healthy adults; prolonged to 21-36 hours in renal impairment; clinically relevant for once-daily dosing and monitoring for accumulation.
Primarily renal (60-70% unchanged), biliary/fecal (10-15%) as active drug and metabolites; remainder metabolized.
Renal (40-60% as unchanged drug via glomerular filtration), biliary/fecal (20-30% as active and inactive metabolites), incomplete excretion leads to enterohepatic recirculation.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic